New insider activity at Bio-Techne ( (TECH) ) has taken place on June 11, 2025.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Director Amy E. Herr has recently sold 1,280 shares of Bio-Techne stock, amounting to a total transaction value of $63,692.
Recent Updates on TECH stock
In the last 24 hours, Bio-Techne’s stock has experienced notable developments. Argus lowered its price target for Bio-Techne from $90 to $65, maintaining a Buy rating, due to challenges such as trade tariffs and reduced funding for academic and government sectors. However, Argus suggests these issues might be temporary, given the improving end markets. Meanwhile, Wells Fargo initiated coverage with an Overweight rating and a $59 price target, citing Bio-Techne’s strong portfolio and potential for sustained revenue and earnings growth in high-growth sectors like proteomic instruments and precision diagnostics. Wells Fargo also views the recent stock pullback as a good entry opportunity.
Spark’s Take on TECH Stock
According to Spark, TipRanks’ AI Analyst, TECH is a Outperform.
Bio-Techne demonstrates robust financial health with strong profitability and low leverage. However, technical indicators suggest bearish momentum, and high valuation raises concerns. The company navigates well through macroeconomic challenges as highlighted in the earnings call, but ongoing legal and tariff issues present risks.
To see Spark’s full report on TECH stock, click here.
More about Bio-Techne
YTD Price Performance: -28.44%
Average Trading Volume: 2,349,129
Technical Sentiment Signal: Sell
Current Market Cap: $8.06B